Metabolic Syndrome and Prostate Cancer Risk: A Population Case-control Study

Hernández-Pérez, Jesús Gibran; Torres‐Sánchez, Luisa; Hernández-Alcaraz, César; López‐Carrillo, Lizbeth; Rodríguez-Covarrubias, Francisco; Vázquez-Salas, Ruth Argelia; Galván-Portillo, Marcia

doi:10.1016/j.arcmed.2022.07.003

Cited by 13 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the present study, we showed real-world evidence concerning the burden and temporal increasing trend of major prostate diseases (BPH and PCa) among patients hospitalized for CVD. Given the close epidemiological relationship based on shared risk factors between prostate diseases and CVD entities, the prevalence of prostate diseases identified in inpatients may be merely part of a larger and more complex issue and is also common in patients with chronic CVD and even in those at risk for CVD ( 14 – 18 ). However, conducting clinical interviews regarding the presence of LUTS and screening tests for prostate diseases in cardiovascular care settings is currently uncommon.…”

Section: Discussionmentioning

confidence: 99%

“…The incidence of major CVDs, such as coronary heart disease and heart failure (HF), generally increases as age, dysregulated cardiometabolic risk factors, and inflammation increase ( 11 – 13 ). Furthermore, metabolic syndrome and coexisting proinflammatory status play a pivotal role in the pathogenesis of major prostate diseases, including BPH and PCa, and disrupted cardiometabolic conditions are strongly associated with an increased prevalence of these prostate diseases ( 14 – 18 ). Hence, prostate diseases share foundational risk factors with CVD and can represent an aspect of cardiometabolic syndrome ( 19 ).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan

Kaneta,

Tanaka,

Nakai

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

IntroductionBenign prostate hyperplasia (BPH) and prostate cancer (PCa) are major prostate diseases that potentially share cardiometabolic risk factors and an elevated risk for cardiovascular disease (CVD). However, the prevalence of prostate diseases among patients with established CVD remains unclear.Materials and methodsThis nationwide retrospective study assessed the prevalence and temporal trend of prostate diseases (i.e., BPH or PCa) among patients hospitalized for CVDs in Japan. We used a claims database (the Japanese Registry of All Cardiac and Vascular Diseases–Diagnosis Procedure Combination), which included data on 6,078,487 male patients recorded from 1,058 hospitals between April 2012 and March 2020. We conducted the Cochran–Armitage trend test and calculated the adjusted odds ratio (aOR) with 95% confidence intervals (CIs).ResultsThe prevalence of prostate diseases over the entire study period was 5.7% (BPH, 4.4%; PCa, 1.6%). When dividing the overall cohort into age categories (<65, 65–74, and ≥75 years old), the prevalence was 1.1%, 4.7%, and 9.9%, respectively (P for trend <0.05). In addition, the annual prevalence showed a modest increasing trend over time. Patients admitted for heart failure (HF) were significantly associated with a higher incidence of coexisting prostate diseases than those admitted for non-HF causes [aOR 1.02 (95% CI, 1.01–1.03)] or acute coronary syndrome [aOR 1.19 (95% CI, 1.17–1.22)].ConclusionsThe nationwide real-world database revealed that the prevalence of prostate diseases is increasing among patients hospitalized for CVD, particularly HF. Attention to detailed causality and continued surveillance are needed to further clarify the clinical characteristics of prostate diseases among patients with CVD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan

Kaneta,

Tanaka,

Nakai

et al. 2023

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

show abstract

“…From the body image perception information at different ages (5,10,20,30,40, and 50 years), 26 three patterns were identified: minor weight changes, characterized by men with a normal weight and a slight increase during adolescence; constantly high body weight, men with high weight since childhood; and body weight increase for men with normal weight during childhood followed by a remarkable increase until reaching overweight between 40 and 50 years old.…”

Section: Weight-change Trajectoriesmentioning

confidence: 99%

Late puberty onset and lack of acne during adolescence reduce high‐grade prostate cancer at adulthood

et al. 2023

Self Cite

View full text Add to dashboard Cite

BackgroundThe interplay between pubertal events patterns (PEP) and prostate cancer (PCa) remains poorly understood. Therefore, we investigated the association of PEP with the odds of PCa, and PCa histological differentiation in men residents of Mexico city.MethodsIn this case–control study, we analyzed the information of 371 incident prostate cancer cases and 775 controls matched on age (±5 years). High‐grade prostate cancer was classified with Gleason score at diagnosis as ≥8. With information related to beard growth, age at maximum height attainment, and acne severity, the k‐medoids algorithm was used to identify three mutually exclusive PEP (early, intermediate, and late). This association was evaluated using multivariable nonconditional logistic regression models.ResultsMen with late PEP, characterized by age at maximum height attainment at around 23 years and no history of acne, was inversely associated with incident (odds ratio [OR]: 0.27; 95% confidence interval [CI]: 0.15–0.48, p trend <0.01) and high‐grade prostate cancer (OR: 0.24; 95% CI: 0.09–0.59, p trend <0.01). Similar associations were observed even after adjusting by IGF‐1 (OR: 0.19; 95% CI: 0.06–0.58) and androgens excretion (OR: 0.21; 95% CI: 0.06–0.66). Only the association between the absence of acne and prostate cancer remained significant after adjustment by these biomarkers.ConclusionsThis study suggests that pubertal characteristics might be helpful in identifying risk groups, among which, secondary prevention strategies could be applied. Also, the results agree with previous work suggesting other potential biological mechanisms involved in the etiology of prostate cancer such as the infectious and inflammatory pathways.

show abstract

“…Studies have commenced investigating the potential association between MetS, its components, and PCa. In a case–control investigation conducted by Jesús Gibran Hernández-Pérez et al, it was indicated that metabolic syndrome exhibited a substantial probability of PCa, while altered lipids, hypertension, and a notable lifetime body weight gain corresponded to an elevated PCa risk 7 . However, there are also studies that suggest the opposite conclusion.…”

Section: Introductionmentioning

confidence: 99%

A Mendelian randomization study between metabolic syndrome and its components with prostate cancer

Xia,

Yu,

Wang

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Previous research has produced inconsistent findings concerning the connection between metabolic syndrome and prostate cancer. It is challenging for observational studies to establish a conclusive causal relationship between the two. However, Mendelian randomization can provide stronger evidence of causality in this context. To examine the causal link between a metabolic composite and its components with prostate cancer, we performed a two-sample Mendelian randomization (MR) study utilizing aggregated data from genome-wide association studies, followed by meta-analyses. In our study, we employed inverse variance weighting as the primary method for MR analysis. Additionally, we assessed potential sources of heterogeneity and horizontal pleiotropy through the Cochran’s Q test and MR-Egger regression. Moreover, we used multivariate MR to determine whether smoking versus alcohol consumption had an effect on the outcomes. We found no causal relationship between metabolic syndrome and its components and prostate cancer(MetS, odds ratio [OR] = 0.95, 95% confidence interval [CI] = 0.738–1.223, p = 0.691; TG, [OR] = 1.02, 95%[CI] = 0.96–1.08, p = 0.59); HDL, [OR] = 1.02, 95% [CI] = 0.97–1.07, p = 0.47; DBP, [OR] = 1.00, 95%[CI] = 0.99–1.01, p = 0.87; SBP, [OR] = 1.00, 95%[CI] = 0.99–1.00, p = 0.26; FBG [OR] = 0.92, 95%[CI] = 0.81–1.05, p = 0.23; WC, [OR] = 0.93, 95%[CI] = 0.84–1.03, p = 0.16). Finally, the MVMR confirms that the metabolic syndrome and its components are independent of smoking and alcohol consumption in prostate cancer. We didn’t find significant evidence to determine a causal relationship between the metabolic syndrome and its components and prostate cancer through MR analysis. Further research is necessary to explore the potential pathogenesis between the two diseases.

show abstract

Metabolic Syndrome and Prostate Cancer Risk: A Population Case-control Study

Cited by 13 publications

References 29 publications

Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan

Prevalence and temporal trends of prostate diseases among inpatients with cardiovascular disease: a nationwide real-world database survey in Japan

Late puberty onset and lack of acne during adolescence reduce high‐grade prostate cancer at adulthood

A Mendelian randomization study between metabolic syndrome and its components with prostate cancer

Contact Info

Product

Resources

About